|
*** FOSAMAX® FEMUR FRACTURES *** The Fox Law Firm is Reviewing Potential FOSAMAX® Claims. Breakdown of the jaw bone Bone fractures Severe musculoskeletal pain Infection Inflammation of the bone marrow
Have you experienced severe health issues – such as bone fractures and breakdown of the jaw bone - following the use of Fosamax®? Have your loved ones suffered adversely after taking Fosamax®? The Fox Law Firm is particularly interested in speaking to those who may have suffered a Femur fracture related to Fosamax® use. If so, you should contact us immediately to protect your legal rights. If you or your loved ones have experienced any of these side effects you may have a claim for legal compensation. Contact The Fox Law Firm for superior legal representation. Fosamax belongs to a specific group of medicines called Bisphosphonates. Fosamax is prescribed to treat and prevent both postmenopausal osteoporosis and steroid-induced osteoporosis. It can also be used to combat the effects of Page’s Disease, which is a chronic disorder of the bone, and which results from irregular breakdown and formation of the patient’s bone tissue. Fosamax works by reducing the speed of the advance of bone loss in the patient while, at the same time, increasing the patient’s bone mass, which can help to prevent bone fractures in the future. The use of Fosamax has been linked with bone loss in the jaw – which is also known as Osteonecrosis of the jaw. Other side-effects linked with Fosamax® may include bone fractures, severe musculoskeletal pain, infection, and inflammation of the bone marrow. Particular signs and symptoms of Osteonecrosis may encompass intense pain in the jaw, gum infections, swelling, numbness, reduced healing following gum surgery, and loose teeth. In January 2008, the Food and Drug Administration (FDA) released an alert that highlighted the possibility of intense and sometimes incapacitating bone, joint, and/or muscle (musculoskeletal) pain in patients to whom Bisphosphonates, such as Fosamax, had been prescribed. The FDA explained in its alert that although severe musculoskeletal pain is included in the prescribing information for all Bisphosphonates, the links between Bisphosphonates and severe musculoskeletal pain may possibly have been overlooked by healthcare professionals – something which may very well have delayed diagnosis, thus prolonging the patient’s pain and/or impairment, and requirung the use of analgesics. The FDA added that the severe musculoskeletal pain in question may begin within days, months, or years after starting a Bisphosphonate. Some patients, the FDA revealed, have reported complete relief from symptoms after discontinuing the Bisphosphonate. Other patients, however, have reported slow or even incomplete resolution. The risk factors for - and incidence of - serious musculoskeletal pain associated with Bisphosphonates are unknown, the FDA noted. The FDA stated further that the intense musculoskeletal pain at issue is in contrast to the acute phase response – which may be characterized by fever, chills, bone pain, myalgias, and arthralgias - that sometimes accompanies initial administration of intravenous Bisphosphonates, and can occur with initial exposure to once-weekly or once-monthly doses of oral Bisphosphonates. The FDA advised U.S. healthcare professionals that they should carefully consider whether Bisphosphonate use might be responsible for severe musculoskeletal pain in patients who have presented these specific symptoms. And, if that is so, or may indeed be the case, they should consider short-term, or even permanent, discontinuation of Fosamax.
Call us today or fill out a form on this website to reach us. Act quickly as delay may cause you to lose your potential legal rights forever. Additional Information:
|
